Market Overview

UPDATE: Wedbush Initiates Coverage on OvaScience on Strong Augment Potential

Related OVAS
Credit Suisse Initiates On Smid-Cap Biotechs, Reveals Favorite Stock Picks
Ovascience Has Lack Of Visibility And 'Sluggish' Uptake, Warns Leerink

In a report published Thursday, Wedbush analyst Zarak Khurshid initiated coverage on OvaScience (NASDAQ: OVAS) with an Outperform rating and $20.00 price target.

In the report, Wedbush noted, “We are initiating coverage of OvaScience (OVAS) with an OUTPERFORM rating and a $20 12-month price target. OVAS is developing products for the treatment of age-related infertility through the enhancement of success rates associated with in vitro fertilization (IVF). The company's lead product, AUGMENT (autologous germline mitochondria energy transfer), involves a method to isolate mitochondria from a woman's egg precursor cells followed by transfer into the egg during IVF, which improves egg energetics and potentially increases the rate of live birth. Additionally, OVAS is developing OvaTure, which represents a next-generation disruptive IVF technology through the creation of young fresh fertilizable eggs from a woman's own egg precursor cells.”

OvaScience closed on Wednesday at $12.00.

Latest Ratings for OVAS

Jan 2016OppenheimerDowngradesOutperformPerform
Jan 2016Credit SuisseInitiates Coverage onUnderperform
Nov 2015Leerink SwannDowngradesOutperformMarket Perform

View More Analyst Ratings for OVAS
View the Latest Analyst Ratings

Posted-In: Wedbush Zarak KhurshidAnalyst Color Initiation Analyst Ratings


Related Articles (OVAS)

View Comments and Join the Discussion!

Get Benzinga's Newsletters